Quigley says QR-443 treats 75% of animal subjects in muscle-wasting trial

By Elaine Rigoli

Tampa, Fla., Aug. 8 - Quigley Pharma said Tuesday that it obtained positive results for its QR-443 compound for the treatment of cachexia, a debilitating and life-threatening muscle-wasting condition. The results of an animal study found a 75% efficacy rate in the treatment of mice with this condition.

The results of the study indicated that 75% of the tested mice injected with 5 mg of QR-433 were protected from cachexia and did not exhibit any significant weight loss compared to untreated control animals, which exhibited a 15% to 25% weight loss at the end of the experiment, the company said in a news release.

QR-443 is an all natural broad spectrum anti-inflammatory compound that is being concurrently studied as a drug for rheumatoid arthritis (under the designation QR-440) in humans and dogs.

The company said it will investigate the possibility of fast-track status with the Food and Drug Administration.

Alternatively, the company said that, due to the importance of these findings, it may consider launching this product as a neutraceutical.

Quigley Pharma, a wholly owned subsidiary of The Quigley Corp., is based in Doylestown, Pa.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.